ulodesine hemiglutarate (MS 001) / MetaShape Pharma - LARVOL DELTA

MetaShape Pharma Presents New Data on MS 001 in Combination with GLP-1 Receptor Agonists at ADA 2026 Scientific Sessions (EIN News) - "The findings demonstrate that MS 001, when combined with semaglutide or tirzepatide, significantly enhances outcomes beyond GLP-1 monotherapy. MS 001 drove deeper weight loss without reducing caloric intake, preserved muscle—a key limitation of GLP-1 therapies—and reduced weight regain following GLP-1 discontinuation...RNA-sequencing analyses comparing semaglutide alone with the semaglutide–MS 001 combination revealed most pronounced transcriptional changes in white adipose tissue. KEGG pathway analysis demonstrated activation of calcium and glucagon signaling pathways, both associated with enhanced thermogenesis....MetaShape is currently preparing a Series A financing of US$10 million to advance MS 001 through clinical proof of concept, with initial efficacy data anticipated in 2029."

New trial • Preclinical • Obesity